View article

This thorough QT/QTc (TQT) study was conducted to evaluate the risk of QT prolongation for verinurad when combined with allopurinol. Verinurad is a novel, urate anion exchanger 1 inhibitor that reduces serum urate levels by promoting urinary excretion of uric acid. It is co‐administered with a xanthine oxidase inhibitor.

The TQT study (NCT04256629) was a randomized, placebo‐controlled, double‐blind, three‐period, crossover study, conducted in healthy volunteers. A total of 24 participants received single doses of verinurad 24 mg extended release, 40 mg immediate release formulation (both co‐administered with allopurinol 300 mg), and matching placebos. The primary endpoint was baseline‐ and placebo‐adjusted Fridericia‐corrected QTcF interval (ΔΔQTcF) at the concentration of interest. A prespecified linear mixed‐effects concentration–QTc model was used to estimate the primary …